Bayer HealthCare Pharmaceuticals Inc, the US-based pharmaceuticals business of Bayer HealthCare LLC, Whippany, NY, announces in a media release that the Betaconnect electronic autoinjector for the treatment of relapsing-remitting multiple sclerosis (MS) has received approval from the US Food and Drug Administration (FDA).
According to a media release from Bayer HealthCare Pharmaceuticals Inc, Betaconnect will be available exclusively to Betaseron (interferon beta-1b) patients beginning in early 2016.
Betaseron is a prescription medicine used to help reduce the number of relapses in people with relapsing forms of MS. After completing the preparation of Betaseron, patients may administer Betaseron using the Betaconnect, which should only be used with the syringes provided in the Betaseron packaging, the release explains.
The Betaconnect offers customizable injection speed and depth settings that enable patients to inject quietly and precisely, as an optional backup reminder function that lets patients know when it’s time for their next injection, and automatic needle insertion and retraction with a visual and audio end-of-dose indication that lets patients know when the injection is complete, the release continues.
For more information, visit Bayer HealthCare Pharmaceuticals Inc.
[Source(s): Bayer HealthCare Pharmaceuticals Inc, PR Newswire]
